BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Daplusiran/Tomligisiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Daplusiran/Tomligisiran\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06537414-10996@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daplusiran/Tomligisiran: Phase 2 readout est. (NCT06537414)
DESCRIPTION:Daplusiran/Tomligisiran\, phase 2\, Chronic Hepatitis B.\nStudy
 : A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Fol
 lowed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB
 )\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06537414
URL:https://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
